Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 1, 2024
Daily News
July 1, 2024
- Moderna Files Spikevax as Booster for Kids Aged 6 Months to 4 Years
July 1, 2024
- Minister Wants Consensus on Future Generic Industry at Upcoming Confab
July 1, 2024
- Daiichi Sankyo’s ADC Arbitration Win Finalized with No Appeal
July 1, 2024
- Healios Pushes Back Definitive MultiStem Deal with Nobelpharma
July 1, 2024
- Xocova Slashes Risk of Hospitalization in Real-World Setting
July 1, 2024
- EA Pharma Grants Global Rights to IBD Drugs to Ensho
July 1, 2024
- Pfizer, Viatris to Copromote Cibinqo, Litfulo in Japan
July 1, 2024
- Kyowa Kirin Files Pen Version of Lumicef in Japan
July 1, 2024
- Eisai’s Alzheimer’s Med Leqembi Now Available in China
July 1, 2024
- Pfizer Seeks Japan Approval for Ulcerative Colitis Drug
July 1, 2024
- Pfizer Files Hemophilia B Gene Therapy in Japan
July 1, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…